公开(公告)号：US20190008836A1

公开(公告)日：2019-01-10

申请号：US15745290

申请日：2016-07-15

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Akira KAIEDA ,  Masaki DAINI ,  Hiroshi NARA ,  Masato YOSHIKAWA ,  Naoki ISHII ,  Masashi TOYOFUKU ,  Kousuke HIDAKA

IPC: A61K31/437 ,  A61P25/28 ,  A61K31/4245 ,  A61K31/4035 ,  A61K31/4439

CPC classification number: A61K31/437 ,  A61K31/4035 ,  A61K31/4245 ,  A61K31/427 ,  A61K31/4439 ,  A61K31/444 ,  A61P25/28 ,  C07D413/04 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04

Abstract: The present invention provide a heterocyclic compound having a HDAC inhibitory action, and useful for the treatment of autoimmune diseases and/or inflammatory diseases, graft versus host disease, cancers, central nervous diseases including neurodegenerative diseases, Charcot-Marie-Tooth disease and the like, and a medicament comprising the compound.The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.

公开(公告)号：US20200377458A1

公开(公告)日：2020-12-03

申请号：US16496530

申请日：2017-03-29

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Yoshito TERAO ,  Masashi TAKAHASHI ,  Ryoma HARA ,  Kousuke HIDAKA ,  Hideki FURUKAWA ,  Takeshi YAMASAKI ,  Shizuo KASAl

IPC: C07D209/96 ,  C07D401/12 ,  A61P3/10 ,  A61P9/04 ,  C07D471/10 ,  C07D491/052 ,  C07D403/12

Abstract: The present invention aims to provide a heterocyclic compound having an IP6K inhibitory action and expected to be useful as a prophylactic or therapeutic agent for—diseases such as cardiac failure, diabetes and the like. A compound represented by the formula (I): wherein each symbol is as defined in the SPECIFICATION, or a salt thereof has an IP6K inhibitory action and is expected to be useful as a prophylactic or therapeutic agent for diseases such as cardiac failure, diabetes and the like.

公开(公告)号：US20170015655A1

公开(公告)日：2017-01-19

申请号：US15210965

申请日：2016-07-15

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Akira KAIEDA ,  Masashi TOYOFUKU ,  Masaki DAINI ,  Hiroshi NARA ,  Masato YOSHIKAWA ,  Naoki ISHII ,  Kousuke HIDAKA

IPC: C07D413/14 ,  C07D417/14 ,  C07D491/08 ,  C07D491/107 ,  C07D413/04 ,  C07D471/04

CPC classification number: C07D413/14 ,  C07D413/04 ,  C07D417/14 ,  C07D471/04 ,  C07D491/08 ,  C07D491/107 ,  C07D498/08

Abstract: The present invention provide a heterocyclic compound having a HDAC inhibitory action, and useful for the treatment of autoimmune diseases and/or inflammatory diseases, graft versus host disease, cancers, central nervous diseases including neurodegenerative diseases, Charcot-Marie-Tooth disease and the like, and a pharmaceutical composition comprising the compound.The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.

Abstract translation: 其中每个符号如说明书中所定义，或其盐。